Rhythm Pharmaceuticals (1RV) Income Statement
Rhythm Pharmaceuticals Income Statement
Last quarter (Q2 2026), Rhythm Pharmaceuticals's total revenue was $71.25M, an increase of 46.91% from the same quarter last year. In Q2, Rhythm Pharmaceuticals's net income was $-49.30M. See Rhythm Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 189.76M | $ 130.13M | $ 77.43M | $ 23.64M | $ 3.15M | |
| $ 170.26M | $ 116.76M | $ 68.13M | $ 21.50M | $ 2.56M | |
| $ 362.28M | $ 382.26M | $ 252.48M | $ 200.66M | $ 172.61M | |
| Depreciation and Amortization | $ 1.34M | $ 1.56M | $ 1.76M | $ 1.67M | $ 1.16M |
| $ -174.12M | $ -238.09M | $ -168.46M | $ -174.25M | $ -68.45M | |
| $ -192.02M | $ -265.50M | $ -184.36M | $ -179.16M | $ -170.06M | |
| $ -4.03M | $ 5.25M | $ 243.00K | $ -1.96M | $ 100.45M | |
| $ -196.04M | $ -260.26M | $ -184.11M | $ -181.12M | $ -69.61M | |
| $ -196.54M | $ -260.60M | $ -184.68M | $ -181.12M | $ -69.61M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.11 | $ -4.34 | $ -3.20 | $ -3.51 | $ -1.37 |
| Diluted EPS | $ -3.11 | $ -4.34 | $ -3.20 | $ -3.51 | $ -1.37 |
| Weighted Average Shares Outstanding | 64.98M | 60.99M | 57.67M | 52.12M | 49.60M |
| Weighted Average Shares Outstanding (Diluted) | 64.98M | 60.99M | 57.67M | 52.12M | 49.60M |
Currency in USD
